Using THBS1 as a therapeutic target could enhance the efficacy of anticancer drugs, with studies showing that positive regulation of THBS1 leads to activation of the PI3K-Akt signaling pathway, promoting tumor growth and resistance to therapy [49]. The gene discussed is AKT1; the disease is neoplasm.